A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, and Preliminary Antitumor Activity of BG-89894(SYH2039) Tablets in Patients With Advanced Solid Tumors
Contact:
NCT Number:
Protocol:
AAAV9440
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this study is to test if the BG-89894 is safe and tolerable, test how the body processes the study drug, and test if it works in patients with advanced solid tumor and with MTAP (methylthioadenosine phosphorylase) deficiency (including those with a loss of MTAP or no MTAP expression) when it is given on its own. MTAP is a biomarker that is tested to detect a deficiency or deletion of the MTAP protein in tumors. The study drug BG-89894 is an investigational drug and has not been approved for use by the Food and Drug Administration (FDA) for the treatment of cancer.
Are you Eligible? (Inclusion Criteria)
- Must be 18 years or older - Patients must be able to provide a tumor tissue sample - Must have evidence of MTAP loss or deficiency
Specialty Area(s)
Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Thyroid Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
